{"id":"https://openalex.org/W2805000756","doi":"https://doi.org/10.1371/journal.pone.0195751","title":"A monoclonal antibody targeting amyloid \u03b2 (A\u03b2) restores complement factor I bioactivity: Potential implications in age-related macular degeneration and Alzheimer\u2019s disease","display_name":"A monoclonal antibody targeting amyloid \u03b2 (A\u03b2) restores complement factor I bioactivity: Potential implications in age-related macular degeneration and Alzheimer\u2019s disease","alternate_titles":[],"publication_year":2018,"publication_date":"2018-05-21","ids":{"openalex":"https://openalex.org/W2805000756","doi":"https://doi.org/10.1371/journal.pone.0195751","mag":"2805000756","pmid":"https://pubmed.ncbi.nlm.nih.gov/29782502","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/5962057"},"language":"en","primary_location":{"id":"doi:10.1371/journal.pone.0195751","doi":"https://doi.org/10.1371/journal.pone.0195751","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0195751","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0195751&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLOS ONE","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2805000756"],"child_works_count":10,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0195751&type=printable","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5076992416","display_name":"Kameran Lashkari","orcid":"https://orcid.org/0000-0003-3855-0246","observed_orcids":["https://orcid.org/0000-0003-3855-0246"]},"institutions":[{"id":"https://openalex.org/I1287163989","display_name":"Massachusetts Eye and Ear Infirmary","ror":"https://ror.org/04g3dn724","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1287163989"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/funding-acquisition","display_name":"Funding acquisition"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/supervision","display_name":"Supervision"},{"id":"https://openalex.org/contributor-roles/validation","display_name":"Validation"}],"raw_author_name":"Kameran Lashkari","raw_affiliation_strings":["Schepens Eye Research Institute, Mass Eye & Ear, Harvard Medical School, Boston, Massachusetts, United States of America"],"raw_orcid":"https://orcid.org/0000-0003-3855-0246","affiliations":[{"raw_affiliation_string":"Schepens Eye Research Institute, Mass Eye & Ear, Harvard Medical School, Boston, Massachusetts, United States of America","institution_ids":["https://openalex.org/I1287163989","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050925379","display_name":"Gianna C Teague","orcid":"https://orcid.org/0000-0002-5715-3847","observed_orcids":["https://orcid.org/0000-0002-5715-3847"]},"institutions":[{"id":"https://openalex.org/I1287163989","display_name":"Massachusetts Eye and Ear Infirmary","ror":"https://ror.org/04g3dn724","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1287163989"]},{"id":"https://openalex.org/I136199984","display_name":"Harvard University","ror":"https://ror.org/03vek6s52","country_code":"US","type":"education","lineage":["https://openalex.org/I136199984"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/project-administration","display_name":"Project administration"}],"raw_author_name":"Gianna Teague","raw_affiliation_strings":["Schepens Eye Research Institute, Mass Eye & Ear, Harvard Medical School, Boston, Massachusetts, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Schepens Eye Research Institute, Mass Eye & Ear, Harvard Medical School, Boston, Massachusetts, United States of America","institution_ids":["https://openalex.org/I1287163989","https://openalex.org/I136199984"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100420433","display_name":"Hong Chen","orcid":"https://orcid.org/0000-0002-5412-7467","observed_orcids":["https://orcid.org/0000-0002-5412-7467"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Hong Chen","raw_affiliation_strings":["Alliance Pharma, Malvern, Pennsylvania, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alliance Pharma, Malvern, Pennsylvania, United States of America","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063686084","display_name":"Yong-Qing Lin","orcid":"https://orcid.org/0000-0002-2563-1365","observed_orcids":["https://orcid.org/0000-0002-2563-1365"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Yong-Qing Lin","raw_affiliation_strings":["Alliance Pharma, Malvern, Pennsylvania, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alliance Pharma, Malvern, Pennsylvania, United States of America","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100678021","display_name":"Sanjay Kumar","orcid":"https://orcid.org/0000-0002-9808-3718","observed_orcids":["https://orcid.org/0000-0002-9808-3718"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Sanjay Kumar","raw_affiliation_strings":["Alternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035784306","display_name":"Megan McLaughlin","orcid":"https://orcid.org/0000-0002-9259-2984","observed_orcids":["https://orcid.org/0000-0002-9259-2984"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Megan M. McLaughlin","raw_affiliation_strings":["Alternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5104365884","display_name":"Francisco J. L\u00f3pez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[{"id":"https://openalex.org/contributor-roles/conceptualization","display_name":"Conceptualization"},{"id":"https://openalex.org/contributor-roles/formal-analysis","display_name":"Formal analysis"},{"id":"https://openalex.org/contributor-roles/funding-acquisition","display_name":"Funding acquisition"},{"id":"https://openalex.org/contributor-roles/investigation","display_name":"Investigation"},{"id":"https://openalex.org/contributor-roles/methodology","display_name":"Methodology"}],"raw_author_name":"Francisco J. L\u00f3pez","raw_affiliation_strings":["Alternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Alternative Discovery & Development, GlaxoSmithKline, King of Prussia, Pennsylvania, United States of America","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5076992416"],"corresponding_institution_ids":["https://openalex.org/I1287163989","https://openalex.org/I136199984"],"apc_list":{"value":2382,"currency":"USD","value_usd":2382},"apc_paid":{"value":2382,"currency":"USD","value_usd":2382},"fwci":1.9138,"has_fulltext":true,"cited_by_count":35,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.84961798,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"13","issue":"5","first_page":"e0195751","last_page":"e0195751"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.9477999806404114,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10993","display_name":"Complement system in diseases","score":0.9477999806404114,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.0364999994635582,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.007499999832361937,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/amyloid-beta","display_name":"amyloid-beta","score":0.8820000290870667},{"id":"https://openalex.org/keywords/complement-factor-i","display_name":"complement factor I","score":0.9750000238418579},{"id":"https://openalex.org/keywords/alternative-complement-pathway","display_name":"alternative complement pathway","score":0.8949999809265137},{"id":"https://openalex.org/keywords/age-related-macular-degeneration","display_name":"age-related macular degeneration","score":0.843999981880188},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9089999794960022},{"id":"https://openalex.org/keywords/drusen","display_name":"drusen","score":0.8640000224113464},{"id":"https://openalex.org/keywords/geographic-atrophy","display_name":"geographic atrophy","score":0.7020000219345093},{"id":"https://openalex.org/keywords/anti-amyloid-monoclonal-antibodies","display_name":"anti-amyloid monoclonal antibodies","score":0.7329999804496765},{"id":"https://openalex.org/keywords/complement-inhibition","display_name":"complement inhibition","score":0.5379999876022339}],"concepts":[{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.8509323000907898},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5710045099258423},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.5191306471824646},{"id":"https://openalex.org/C2777633098","wikidata":"https://www.wikidata.org/wiki/Q2736051","display_name":"Amyloid (mycology)","level":2,"score":0.48607924580574036},{"id":"https://openalex.org/C14356644","wikidata":"https://www.wikidata.org/wiki/Q14911975","display_name":"Factor H","level":4,"score":0.4849124550819397},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.47555798292160034},{"id":"https://openalex.org/C111684460","wikidata":"https://www.wikidata.org/wiki/Q334848","display_name":"Complement system","level":3,"score":0.461296409368515},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.448002427816391},{"id":"https://openalex.org/C179369057","wikidata":"https://www.wikidata.org/wiki/Q20970075","display_name":"Complement factor I","level":4,"score":0.44484689831733704},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.4434865117073059},{"id":"https://openalex.org/C163864487","wikidata":"https://www.wikidata.org/wiki/Q6901461","display_name":"Monoclonal","level":4,"score":0.41175681352615356},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3479377329349518},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.2756724953651428},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.17435795068740845}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003167","descriptor_name":"Complement Activation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D016022","descriptor_name":"Case-Control Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016229","descriptor_name":"Amyloid beta-Peptides","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016229","descriptor_name":"Amyloid beta-Peptides","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D017244","descriptor_name":"Complement Factor I","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true}],"locations_count":6,"locations":[{"id":"doi:10.1371/journal.pone.0195751","doi":"https://doi.org/10.1371/journal.pone.0195751","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0195751","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0195751&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLOS ONE","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:4935542","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5962057","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:5962057","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5962057/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLoS One","raw_type":"Text"},{"id":"pmid:29782502","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29782502","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PloS one","raw_type":"Journal Article"},{"id":"pmh:oai:dash.harvard.edu:1/37298388","doi":null,"is_oa":true,"landing_page_url":"http://nrs.harvard.edu/urn-3:HUL.InstRepos:37298388","pdf_url":null,"source":{"id":"https://openalex.org/S4306401540","display_name":"Digital Access to Scholarship at Harvard (DASH) (Harvard University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I136199984","host_organization_name":"Harvard University","host_organization_lineage":["https://openalex.org/I136199984"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:dda9a9bcc1924f6bb53e1671bb1ac143","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/dda9a9bcc1924f6bb53e1671bb1ac143","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"PLoS ONE, Vol 13, Iss 5, p e0195751 (2018)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1371/journal.pone.0195751","doi":"https://doi.org/10.1371/journal.pone.0195751","is_oa":true,"landing_page_url":"https://doi.org/10.1371/journal.pone.0195751","pdf_url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0195751&type=printable","source":{"id":"https://openalex.org/S202381698","display_name":"PLoS ONE","issn_l":"1932-6203","issn":["1932-6203"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","doaj","dongbi-c","doyens","erih-plus","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315706","host_organization_name":"Public Library of Science","host_organization_lineage":["https://openalex.org/P4310315706"],"host_organization_lineage_names":["Public Library of Science"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"PLOS ONE","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9922999739646912,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G6797018359","display_name":null,"funder_award_id":"4100111","funder_id":"https://openalex.org/F4320307773","funder_display_name":"GlaxoSmithKline"}],"funders":[{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2805000756.pdf","grobid_xml":"https://content.openalex.org/works/W2805000756.grobid-xml"},"referenced_works_count":38,"referenced_works":["https://openalex.org/W129305155","https://openalex.org/W159419684","https://openalex.org/W1272423043","https://openalex.org/W1565463013","https://openalex.org/W1710437513","https://openalex.org/W1813781971","https://openalex.org/W1930918755","https://openalex.org/W1965031576","https://openalex.org/W1978753457","https://openalex.org/W1981728813","https://openalex.org/W1983877288","https://openalex.org/W1985731048","https://openalex.org/W1989747234","https://openalex.org/W1994797655","https://openalex.org/W2001661375","https://openalex.org/W2009744995","https://openalex.org/W2033662964","https://openalex.org/W2047202120","https://openalex.org/W2060767100","https://openalex.org/W2068967648","https://openalex.org/W2075017815","https://openalex.org/W2076151830","https://openalex.org/W2086188106","https://openalex.org/W2088749707","https://openalex.org/W2092148373","https://openalex.org/W2098670913","https://openalex.org/W2113082007","https://openalex.org/W2115932454","https://openalex.org/W2122106651","https://openalex.org/W2136501493","https://openalex.org/W2169333648","https://openalex.org/W2170121491","https://openalex.org/W2220828898","https://openalex.org/W2347205644","https://openalex.org/W2460245075","https://openalex.org/W2584169772","https://openalex.org/W2588876189","https://openalex.org/W3145351529"],"related_works":["https://openalex.org/W1710437513","https://openalex.org/W2091890377","https://openalex.org/W1978753457","https://openalex.org/W3134984086","https://openalex.org/W2263018236","https://openalex.org/W2028283509","https://openalex.org/W4235484518","https://openalex.org/W2003101845","https://openalex.org/W4304695079","https://openalex.org/W1983877288"],"abstract_inverted_index":{"Activation":[0],"of":[1,12,27,65,73,107,121,141,242,246],"the":[2,10,74,142,150,211,247,259],"alternative":[3,248],"complement":[4,31,249],"cascade":[5,250],"has":[6],"been":[7,135],"implicated":[8],"in":[9,63,78,103,119,127,146,202,231,239,258],"pathogenesis":[11],"age":[13],"related":[14],"macular":[15],"degeneration":[16],"(AMD)":[17],"and":[18,44,69,100,109,126,155,169,199,213,228,237,244],"Alzheimer's":[19],"disease":[20,189,260],"(AD).":[21],"Amyloid":[22],"\u03b2":[23],"(A\u03b2),":[24],"a":[25,50,84,181,197,255],"component":[26],"drusen,":[28],"may":[29],"promote":[30],"activation":[32,245],"by":[33,153,226],"inhibiting":[34],"CFI":[35,42,56,61,89,117,151,160,167,204,220],"bioactivity.":[36,57,161],"We":[37,58],"determined":[38],"whether":[39,45],"A\u03b2":[40,48,108,148,227,243],"reduced":[41,149],"bioactivity":[43,62,90,118,152,170,205],"antibodies":[46],"against":[47],"including":[49],"monoclonal":[51],"antibody,":[52],"GSK933776":[53,75,138,143,158,209],"could":[54],"restore":[55],"also":[59],"measured":[60,116],"plasma":[64,120,166],"subjects":[66,123,130,163,192],"with":[67,124,131,137,157,164,188,193,208],"AMD":[68,79,236],"AD.":[70,147],"In":[71,162,191],"support":[72],"development":[76,144],"program":[77,145],"(geographic":[80],"atrophy),":[81],"we":[82,115,179,195],"developed":[83],"quantitative":[85],"assay":[86],"to":[87,95,98,253],"measure":[88],"based":[91],"on":[92],"its":[93],"ability":[94],"cleave":[96],"C3b":[97],"iC3b,":[99],"repeated":[101],"it":[102],"presence":[104],"or":[105],"absence":[106],"anti-A\u03b2":[110],"antibodies.":[111],"Using":[112],"this":[113],"assay,":[114],"194":[122],"AMD,":[125,165],"samples":[128],"from":[129,175],"AD":[132],"that":[133,219],"had":[134],"treated":[136],"as":[139,235],"part":[140],"5-fold":[154],"pre-incubation":[156],"restored":[159],"levels":[168],"were":[171],"not":[172],"significantly":[173],"different":[174],"non-AMD":[176],"controls.":[177],"However,":[178],"detected":[180],"positive":[182],"linear":[183],"trend,":[184],"suggesting":[185],"increasing":[186],"activity":[187,222],"severity.":[190],"AD,":[194,238],"observed":[196],"10%":[198],"27%":[200],"increase":[201],"overall":[203],"after":[206],"treatment":[207],"during":[210],"second":[212],"third":[214],"dose.":[215],"Our":[216],"studies":[217],"indicate":[218],"enzymatic":[221],"can":[223],"be":[224,229],"inhibited":[225],"altered":[230],"proinflammatory":[232],"diseases":[233],"such":[234],"which":[240],"deposition":[241],"are":[251],"believed":[252],"play":[254],"key":[256],"role":[257],"process.":[261]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2805000756","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":6},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":3}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2018-06-01T00:00:00"}
